Advertisement

An experimental Alzheimer's drug outperforms one just approved by the FDA

The image shows amyloid plaques in the brains of three patients in the early stages of Alzheimer's. Those plaques are greatly reduced in the first two patients, who got donanemab, but remain unchanged in a patient who received no treatment. (Eli Lilly and Company)
The image shows amyloid plaques in the brains of three patients in the early stages of Alzheimer's. Those plaques are greatly reduced in the first two patients, who got donanemab, but remain unchanged in a patient who received no treatment. (Eli Lilly and Company)

Related:

Advertisement

More from WBUR

Listen Live
Close